| 2.06 0.02 (0.98%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.57 | 1-year : | 2.79 |
| Resists | First : | 2.2 | Second : | 2.39 |
| Pivot price | 2.07  |
|||
| Supports | First : | 1.89 | Second : | 1.58 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 2.06 |
| MA(100) : | 2.94 |
MA(250) : | 3.22 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 30.4 |
D(3) : | 34.2 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 5.63 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRDF ] has closed above bottom band by 45.1%. Bollinger Bands are 78.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.08 - 2.09 | 2.09 - 2.1 |
| Low: | 1.96 - 1.97 | 1.97 - 1.98 |
| Close: | 2.04 - 2.06 | 2.06 - 2.08 |
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Thu, 28 Aug 2025
Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Wed, 30 Jul 2025
Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
Tue, 29 Jul 2025
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update - GlobeNewswire
Tue, 29 Jul 2025
Cardiff Oncology Announces Positive Data from Ongoing - GlobeNewswire
Tue, 29 Jul 2025
Breakthrough: New Cancer Drug Achieves 49% Response Rate vs 30% Standard Care in Colorectal Cancer Trial - Stock Titan
Tue, 29 Jul 2025
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 6.49e+007 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 18,840 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.395e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 212.3 % |
| Return on Equity (ttm) | -48 % |
| Qtrly Rev. Growth | 545000 % |
| Gross Profit (p.s.) | -20.16 |
| Sales Per Share | -71.83 |
| EBITDA (p.s.) | -3.19219e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 2.99 |
| Dividend | 0 |
| Forward Dividend | 1.591e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|